Now Available: Spotlight on Attovia CEO Tao Fu. Click here to read.
"This is an exciting direction because it offers opportunities for actual cures," said Illumina Ventures partner Wouter Meuleman. "The ability to correct single-nucleotide variations, or even replace entire genes, will change how we practice medicine."
Kallyope, Inc., a leading biotechnology company focused on identifying and developing therapeutics involving the gut-brain axis, today announced the closing of a $236 million Series D financing co-led by Mubadala Investment Company and The Column Group, along with participation from other new and existing investors (including Illumina Ventures). The funds will be used to advance the company’s ...
Biotech firm Protillion Biosciences has closed an $18 million Series A financing round funded by Arch Venture Partners and Illumina Ventures.
“While most liquid biopsy efforts focus on circulating tumor DNA (ctDNA), Alamar is taking a different path, looking for circulating cancer-associated protein biomarkers,” said Nick Naclerio, Ph.D., Founding Partner of Illumina Ventures. “This is mostly undiscovered territory and could ultimately lead to highly sensitive diagnostics that find cancer and other diseases early when they are most ...
Your screen does not meet the requirements for generating previews. Adjust your screen width to exactly 1920px before proceeding, otherwise you'll not be able to generate previews.
